All In Biotech

Drug Trial Radar · NCT07679828

Polypills Approach for Multiple Cardiovascular Risk Factors

Polypills Approach for Multiple Cardiovascular Risk Factors (PACIF) : a Multicentre, Open-label, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 8,252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8,252

Planned (sponsor's estimate)

Start

Jul 11, 2026

Primary completion

Dec 31, 2029

Study completion Mar 1, 2030

Sponsor

Lead sponsor
China Medical University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for the integrated management of hypertension, dyslipidemia, and type 2 diabetes among adults aged 50 to 75 years without prior cardiovascular disease in China. The trial will evaluate whether a fixed-dose combination strategy improves the 10-year cardiovascular disease risk estimated using the PREVENT equations at Phase 1. Participants will be further followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and improves cognitive outcomes compared with usual care at Phase 2.

Conditions

  • Hypertension
  • Dyslipidemia
  • Diabetes

Interventions

  • Fixed-Dose Combination StrategyDrug

    Participants assigned to the intervention group will receive a fixed-dose combination strategy for the integrated control of blood pressure, lipid, and glucose. Eight prespecified fixed-dose formulations will be used, differing in antihypertensive intensity and rosuvastatin dose. All formulations will include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe 10 mg, and dapagliflozin 10 mg, with indapamide 2.5 mg included in selected formulations. The olmesartan medoxomil/amlodipine dose will range from 5/1.25 mg to 20/5 mg, and the rosuvastatin dose will be either 5 mg or 10 mg. Treatment will be selected and adjusted among the prespecified fixed-dose formulations according to participants' blood pressure levels, treatment targets, tolerability, and safety. If the prespecified blood pressure, lipid, or glycemic targets are not achieved despite the highest fixed-dose regimen, additional open-label medications may be prescribed according to guideline recommendations.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 10-year CVD riskTime frame: 12 months
  2. Composite cardiovascular disease outcomeTime frame: 36 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Henan University of Chinese Medicine

    Zhengzhou, Henan, China · Not yet recruiting

  • Affiliated Hospital of Chifeng University

    Chifeng, Inner Mongolia, China · Recruiting

  • Tongliao People's Hospital

    Tongliao, Inner Mongolia, China · Not yet recruiting

  • Kunshan Hospital of Chinese Medicine

    Kunshan, Jiangsu, China · Not yet recruiting

  • Suzhou Wujiang District Hospital of Traditional Chinese Medicine

    Suzhou, Jiangsu, China · Not yet recruiting

  • The Fifth People's Hospital of Wujiang District

    Suzhou, Jiangsu, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • Taixing Second People's Hospital

    Taizhou, Jiangsu, China · Not yet recruiting

  • Central Hospital of Jinzhou

    Jinzhou, Liaoning, China · Recruiting

  • Panjin Central Hospital

    Panjin, Liaoning, China · Not yet recruiting

  • First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Tieling Central Hospital

    Tieling, Liaoning, China · Recruiting

  • Tiemei General Hospital of Liaoning Health Industry Group

    Tieling, Liaoning, China · Recruiting

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.